We investigated the acute effects on the renin-angiotensin system and the pharmacokinetic properties of the angiotensin converting enzyme inhibitor enalapril and its potent active diacid metabolite. Seventeen patients with essential hypertension (EH group) and five hypertensive patients with chronic renal failure (CRF group) were enrolled for this study. In the EH group, the biological half life (t
1/2) of the diacid was 8.4 hours, the maximum serum concentrations (Cmax) and areas under the curve ([AUC]
24 0) of enalapril and its diacid were 50.6 ng/ml and 32.2 ng/ml, and 171.6 ng h/ml and 413.9 ng⋅h/ml, respectively. In the CRF group, the t
l/2 of the diacid was 10.9 hours, the mean Cmax and [AUC]
24 0 of enalapril and its diacid were 86.9 ng/ml and 109.8 ng/ml, and 330.0 ng⋅h/ml and 1709.7 ng⋅h/ml, respectively. The renal clearance of total compounds (enalapril + its diacid) in the CRF group (19.6 ml/min) was significantly lower than that in the EH group (110.5 ml/min). A significant positive correlation was found between the inverse of the creatinine clearance (Ccr) and [AUC]
24 0 (r=0.70, p<0.001; [AUC]
24 0 = 10521.6 x 1/Ccr+ 388.1). In conclusion, these results indicate that enalapril may represent a useful antihypertensive agent for the control of blood pressure in patients with chronic renal failure.
抄録全体を表示